{"id":"W4388247185","doi":"10.1016/j.esmoop.2023.102049","title":"Futibatinib: second EMA approval for FGFR inhibitor in cholangiocarcinoma","year":2023,"lang":"en","type":"editorial","venue":"ESMO Open","topic":"Cholangiocarcinoma and Gallbladder Cancer Studies","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":true,"ca_institutions":"University Health Network; Toronto General Hospital; Princess Margaret Cancer Centre","funders":"Sirtex Medical; Eisai; Ipsen; BeiGene; Sociedad Española de Oncología Médica; Incyte; Horizon 2020 Framework Programme; Boston Scientific Corporation; AstraZeneca; Mylan; Servier; European Commission; Pfizer; Amgen","keywords":"Fibroblast growth factor receptor; Cancer research; PI3K/AKT/mTOR pathway; Medicine; Cancer; Protein kinase B; Intrahepatic Cholangiocarcinoma; Oncology; Internal medicine; Fibroblast growth factor; Receptor; Biology; Signal transduction; Genetics","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0009082069,0.0006233868,0.001595579,0.000377684,0.0001384337,0.0002296112,0.0008220429,0.0009416118,0.0001777783],"category_scores_gemma":[0.001448796,0.0005802403,0.0004098277,0.0004826049,0.0001051935,0.0002074525,0.0008888515,0.001161577,0.0001661567],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003955399,"about_ca_system_score_gemma":0.001220827,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001926441,"about_ca_topic_score_gemma":0.007397281,"domain_scores_codex":[0.9964384,0.00007063898,0.0007838164,0.001180072,0.0007093741,0.0008176753],"domain_scores_gemma":[0.9972575,0.001084671,0.0002795607,0.0008362891,0.0003198045,0.0002221375],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0008399046,0.0001264901,0.003031318,0.0008892773,0.0003376906,0.000193895,0.0009258363,3.102286e-7,0.00001432921,0.00002790095,0.9918423,0.001770786],"study_design_scores_gemma":[0.0070199,0.000693735,0.03273659,0.0006908434,0.0002443965,0.00000725934,0.0003887715,0.00001161423,0.0001250127,0.0001124422,0.9573876,0.000581852],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","genre_codex":"editorial","genre_gemma":"editorial","genre_scores_codex":[0.006995703,0.001016477,0.000006665036,0.001185071,0.9724391,0.004855347,0.0009496629,0.0003018969,0.01225006],"genre_scores_gemma":[0.0073019,0.0001355328,0.0005882478,0.000303258,0.9463794,0.002557846,0.00325596,0.0004990719,0.03897879],"genre_candidate":"editorial","genre_consensus":"editorial","teacher_disagreement_score":0.03445468,"threshold_uncertainty_score":0.9996649,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0439699449041167,"score_gpt":0.3597103993650207,"score_spread":0.315740454460904,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}